01—Abstract
Summary
Summary of the 10-K filed February 25, 2015. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. reported significant growth in 2014, driven primarily by the successful launches of its Hepatitis C virus (HCV) treatments, Sovaldi and Harvoni.
Total revenues surged to $24.9 billiona, a substantial increase from $11.2 billion in 2013, with antiviral products accounting for the vast majority of sales. The company also saw strong performance from its HIV portfolio, particularly single-tablet regimens like Stribild and Complera/Eviplera. Despite the strong revenue growth, Gilead experienced a notable increase in operating expenses, including research and development (R&D) and selling, general, and administrative (SG&A) costs, largely due to investments in pipeline progression and expanding commercial infrastructure.
The company ended the year with a robust cash position of $11.7 billionb, underscoring its financial strength. Gilead also highlighted ongoing efforts to expand access to its medications in developing countries through licensing agreements.
Looking ahead, Gilead anticipates continued net product sales growth, supported by expanded access to its HCV treatments and the potential launch of new HIV therapies. However, the company faces ongoing challenges including pricing pressures, competition in the HCV market, potential regulatory hurdles, and significant ongoing litigation related to its key products, particularly sofosbuvir.
02—Key points
Key Highlights
- Gilead Sciences achieved a significant revenue milestone in 2014, with total revenues reaching $24.9 billion, more than doubling from $11.2 billion in 2013, primarily driven by the strong performance of its Hepatitis C (HCV) treatments, Sovaldi and Harvoni.
- The company's HIV franchise continued its strong performance, with single-tablet regimens like Stribild and Complera/Eviplera showing significant sales increases.
- Research and Development (R&D) expenses increased by 35% to $2.9 billion, reflecting continued investment in pipeline development across key therapeutic areas.
- Selling, General, and Administrative (SG&A) expenses saw a substantial 76% increase to $3.0 billion, driven by business expansion, particularly in liver diseases and oncology, and increased Branded Prescription Drug (BPD) fees.
- Gilead ended 2014 with a strong liquidity position, reporting $11.7 billion in cash, cash equivalents, and marketable securities.
- The company is actively managing intellectual property and faces ongoing litigation, notably with Idenix Pharmaceuticals and Merck, concerning its sofosbuvir patents.
- Gilead is committed to expanding global access to its medicines, evidenced by non-exclusive licensing agreements with generic manufacturers for HCV and HIV drugs in developing countries.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2014, Gilead Sciences, Inc. kept $0.49.
- Revenue$24.89B100.0%
- Cost of revenue−$3.79B15.2%
- Gross profit$21.10B84.8%
- Operating costs−$5.84B23.5%
- Operating income$15.27B61.3%
- Interest, other & tax−$3.16B12.7%
- Net income$12.10B48.6%
Where FY2014 revenue went
$24.89B- Net income: $12.10B, 49% of revenue
- Cost of revenue: $3.79B, 15% of revenue
- Interest, other & tax: $3.16B, 13% of revenue
- R&D: $2.85B, 11% of revenue
- SG&A: $2.98B, 12% of revenue
Kept 49% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 25, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $24.89B$11.20B | +122.2% |
| Cost of Revenue | $3.79B$2.86B | +32.5% |
| Gross Profit | $21.10B$8.34B | +152.9% |
| R&D Expenses | $2.85B$2.12B | +34.6% |
| SG&A Expenses | $2.98B$1.70B | +75.6% |
| Operating Expenses | $9.63B$6.68B | +44.1% |
| Operating Income | $15.27B$4.52B | +237.4% |
| Interest Expense | $412.00M$307.00M | +34.2% |
| Net Income | $12.10B$3.08B | +293.5% |
| EPS (Basic) | $7.95$2.01 | +295.5% |
| EPS (Diluted) | $7.35$1.81 | +306.1% |
| Shares Outstanding (Basic) | 1.52B1.53B | −0.5% |
| Shares Outstanding (Diluted) | 1.65B1.70B | −2.8% |
05—Questions
Frequently Asked Questions
What were the main drivers of Gilead's revenue growth in 2014?
Gilead's revenue growth in 2014 was primarily driven by the successful launches and strong sales uptake of its Hepatitis C virus (HCV) treatments, Sovaldi and Harvoni. The company's HIV franchise also contributed significantly to revenue growth.
How did Gilead's R&D and SG&A expenses change in 2014?
Gilead's R&D expenses increased by 35% to $2.9 billion, reflecting ongoing investment in its product pipeline. SG&A expenses rose by 76% to $3.0 billion, largely due to business expansion efforts and increased BPD fees.
What is Gilead's financial position at the end of 2014?
Gilead ended 2014 with a strong financial position, reporting $11.7 billion in cash, cash equivalents, and marketable securities, and generating $12.8 billion in cash flow from operations. The company also issued $8.0 billion in senior unsecured notes.
What are the key risks and challenges facing Gilead moving forward?
Gilead faces several risks and challenges, including increasing pricing pressure in the HCV market, competition from other pharmaceutical companies, ongoing litigation related to its key products, particularly sofosbuvir patents, and potential regulatory changes that could impact healthcare spending and reimbursement.
06—Continue